All Posts Tagged With: "SLE"
(HGSI) Human Genome Sciences to Seek Drug Approval in Second Quarter
Human Genome Sciences Inc. (HGSI) announced recently that it intends to seek approval for its potential blockbuster lupus drug candidate Benlysta during the second quarter of 2010 in the United States and...
(SLE) Sara Lee Corporation – Earnings Estimates Advance
Sara Lee Corp. (SLE) gapped open on its strong Q1 results from early November on lower costs and strong North American sales, driving shares to a new 52-weke high above $12.
Company...
(PG) The Procter & Gamble Company Acquires Ambi Pur Brand From Sara Lee Corporation
The Procter & Gamble Company (PG) signed an agreement to acquire the Ambi Pur Brand from Sara Lee Corporation (SLE) for €320 million...
(NWSA) Q4 S&P Earnings to More than Double – Earnings Trends
Key Points:
• Earnings Surprise Ratio (#beat/#miss) at 5.28, almost double normal
• Median Earnings Surprise 7.14%, very strong
• Year-over-year Earnings Growth Ratio (# Pos Growth/# Neg Growth) at 0.81
• ...
(HGSI) Human Genome Sciences to Sell 12.5 Million Shares
Human Genome Sciences Inc. (HGSI) announced that it intends to sell up to 12.5 million shares to raise money for the development of its potential blockbuster lupus drug Benlysta and other business activities.
The...
(HGSI) Human Genome Sciences Begins Trial
Recently, Human Genome Sciences, Inc. (HGSI) and Aegera Therapeutics announced the initiation of dosing in a phase I clinical trial to evaluate the safety and tolerability of its lead inhibitor-of-apoptosis...
(HGSI) Human Genome Sciences Reports Lower Q3 Loss
Human Genome Sciences, Inc. (HGSI) reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. The company reported a...